Call Is Confidential & Toll Free


Gilenya is a sphingosine 1-phosphate receptor modulator indicated and approved for the treatment of relapsing-remitting multiple sclerosis.

Gilenya causes a transient reduction in heart rate and AV conduction at treatment initiation. Potential to prolong the QT interval. Effects on immune cell numbers in the blood- decreased lymphocyte counts. Mild decrease in the neutrophil count- about 80% of original pre-therapy count. Compared to placebo, antigen-specific IgM titers were decreased by 91% and 25% in response to KLH and PPV, respectively. IgG titers were decreased by 45% and 50%, in response to KLH and PPV. The capacity to mount a skin delayed-type hypersensitivity reaction to Candida and tetanus toxoid was decreased by approximately 30% in subjects on gilenya 0.5 mg daily, compared to placebo. Immunologic responses were further decreased with gilenya 1.25 mg (a dose higher than recommended for MS). Single gilenya doses ≥5 mg (10-fold the recommended dose) are associated with a dose-dependent increase in airway resistance.

Bradyarrhythmia and Atrioventricular Blocks Risk of infections Macular Edema Respiratory Effects Hepatic Effects Fetal Risk Blood Pressure Effects Immune System Effects Following Gilenya Discontinuation


Drug: Gilenya
Strength: 0.5 Mg
Pill Imprint: FTY 0.5 Mg
Color: White & Yellow
Shape: Capsule-shape

View Images & Details
Disclaimer: We strive to ensure that the content on pilladdictions.com is current and factual at the time it was written. However, because new information and discoveries are always becoming available, we are not making any representations or warranties with respect to this content. Please always rely on the guidance of your physician for information about the drugs you are taking and the impacts they may or may not have on your health.

Questions About Prescription Drug Addiction?

(888) 740-2069

Questions About Prescription Drug Addiction?